Research Article, J Clin Exp Oncol Vol: 2 Issue: 4
Survivin and Livin with Angiogenesis in Cancer
Mutlu Dogan* | |
Ankara Numune Training and Research Hospital, Dept of Medical Oncology, Ankara, Turkey | |
Corresponding author : Mutlu Dogan Associate Professor, Ankara Numune Training and Research Hospital, Department of Medical Oncology, Ankara, Turkey, Tel: +903125084600; Fax: +903125084914 E-mail: mutludogan1@yahoo.com |
|
Received: September 09, 2013 Accepted: November 28, 2013 Published: December 16, 2013 | |
Citation: Dogan M (2013) Survivin and Livin with Angiogenesis in Cancer. J Clin Exp Oncol 2:4. doi:10.4172/2324-9110.1000115 |
Abstract
Survivin and Livin with Angiogenesis in Cancer
Tumor promotion and progression depends on a complex interaction between cellular signaling pathways, apoptosis, angiogenesis and other mechanisms. Understanding these mechanisms and their interactions led to the development of targeted therapies such as antiangiogenic agents and mTOR inhibitors in cancer. In recent years, inhibitors of apoptosis proteins (IAP) like survivin and livin seem promising as new targets for cancer therapy. In this report, the role of survivin and livin with angiogenesis will be discussed.